Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab

Mingchao Shi(Jilin University), Jie Zhu(Karolinska University Hospital)

Frontiers in Aging Neuroscience

April 12, 2022

10.3389/fnagi.2022.870517

Cited by 257

Related Papers

1,25‐dihydroxyvitamin D<sub>3</sub>‐induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells

|Immunology|2017|96

Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications

|Journal of Neuroscience Research|2017|47

Neuroprotective effect of matrine on MPTP-induced Parkinson's disease and on Nrf2 expression

|Oncology Letters|2016|43

Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer’s disease via impacting on peripheral innate immune cells

|Journal of Neuroinflammation|2024|43

Role of regulatory b cells in neuroimmunologic disorders

|Journal of Neuroscience Research|2016|42